top of page
Browse by category
Search
Innovent's mazdutide accepted by China’s NMPA for chronic weight management
Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...
Mazdutide demonstrates significant weight loss efficacy and multiple metabolic benefits
The 48-week outcomes from a Phase 2 clinical study of higher dose (9mg) mazdutide in Chinese subjects with obesity have demonstrated...
Mazdutide anti-obesity drug achieves 11.7% body weight loss at 12-weeks
Innovent Biologics has announced that the results of a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and...
Browse by tag
bottom of page